Literature DB >> 85433

Effect of 5-azacytidine on cytoplasmic ribosomal and messenger ribonucleic acids in BSC-1 cells.

Y Reuveni, L J Rosenthal.   

Abstract

5-Azacytidine (5-AzaCR) inhibited the accumulation of 28S and 18S ribonucleic acids (RNAs) in the cytoplasm of treated cells. The inhibition of 28S and 18S RNAs in the cytoplasm of BSC-1 cells was dependent upon the concentration of 5-AzaCR employed and the time of exposure. At a concentration of 200 mug/ml for 2 h, 5-AzaCR inhibited the cytoplasmic 28S and 18S RNAs by 80 and 70%, respectively. The 28S and 18S RNAs that appeared in the cytoplasm of treated cultures had no altered secondary structure, as analyzed by polyacrylamide gel electrophoresis. The inhibitory effect on cytoplasmic 28S and 18S RNAs was found to be reversible, and removal of 5-AzaCR from treated cultures allowed the accumulation of cytoplasmic 28S and 18S RNAs to almost normal levels by 20 h. 5-AzaCR appeared to have no effect upon the synthesis and processing of polyadenylic acid-containing messenger RNA in treated cultures. However, the formation of the 80S ribosomal subunit appeared to be inhibited in drug-treated cells. Moreover, 5-AzaCR treatment caused a disaggregation of polyribosomes and an accumulation of 80S ribosomes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 85433      PMCID: PMC352638          DOI: 10.1128/AAC.15.2.235

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Inhibition of viral protein synthesis in monkey cells treated with interferon late in simian virus 40 lytic cycle.

Authors:  E Yakobson; C Prives; J R Hartman; E Winocour; M Revel
Journal:  Cell       Date:  1977-09       Impact factor: 41.582

2.  The control of SV40 transcription during a lytic infection: late RNA synthesis in the presence of inhibitors of DNA replication.

Authors:  L J Rosenthal; M Brown
Journal:  Nucleic Acids Res       Date:  1977-03       Impact factor: 16.971

3.  Replication of vesicular stomatitis virus. II. Separation and characterization of virus-specific RNA species.

Authors:  A L Schincariol; A F Howatson
Journal:  Virology       Date:  1972-09       Impact factor: 3.616

4.  Tyrosine transaminase induction: differential effect of 5-azacytidine on liver and hepatoma 5123D.

Authors:  I B Levitan; H P Morris; T E Webb
Journal:  Biochim Biophys Acta       Date:  1971-06-30

5.  The mechanism of inhibition of protein synthesis by 5-azacytidine in HeLa cells.

Authors:  M Reichman; S Penman
Journal:  Biochim Biophys Acta       Date:  1973-10-12

6.  Destructive processing of the 45-S ribosomal precursor in the presence of 5-azacytidine.

Authors:  M Reichman; D Karlan; S Penman
Journal:  Biochim Biophys Acta       Date:  1973-02-23

7.  Alteration of ribosomal precursor RNA in Novikoff hepatoma cells by 5-azacytidine. Studies on methylation of 45S and 32S RNA.

Authors:  J W Weiss; H C Pitot
Journal:  Arch Biochem Biophys       Date:  1974-12       Impact factor: 4.013

8.  Isolation and characterization of poly(A)-containing polyoma "early" and "late" messenger RNAs.

Authors:  L J Rosenthal
Journal:  Nucleic Acids Res       Date:  1976-03       Impact factor: 16.971

9.  Effects of 5-azacytidine on nucleolar RNA and the preribosomal particles in Novikoff hepatoma cells.

Authors:  J W Weiss; H C Pitot
Journal:  Biochemistry       Date:  1975-01-28       Impact factor: 3.162

10.  Biological effects of 5-azacytidine in eukaryotes.

Authors:  A Cihák
Journal:  Oncology       Date:  1974       Impact factor: 2.935

View more
  3 in total

1.  Azapyrimidine analogues: inhibition of viral DNA synthesis and protein synthesis in SV40 infected BSC-1 cells.

Authors:  M Johnson-Thompson; D Albury
Journal:  In Vitro Cell Dev Biol       Date:  1988-11

2.  Effect of azacytidine on Simian Virus 40 nucleoprotein complexes.

Authors:  M Johnson-Thompson; L J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

3.  The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).

Authors:  Sarit Assouline; Eftihia Cocolakis; Katherine L B Borden
Journal:  Cancers (Basel)       Date:  2012-11-02       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.